StockCIK 2020932

AgomAb Therapeutics NV (AGMB): Insider Trades and Fund Holdings

In the past 12 months, AgomAb Therapeutics NV insiders reported 7 open-market purchases worth $400K and 0 sales worth $0.

7Insider buys, 12 months

$400KBought by insiders, 12 months

$0Sold by insiders, 12 months

0Tracked funds holding

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 22, 2026.

Recent AGMB insider trades
Filed	Traded	Insider	Role	Type	Shares	Price ($)	Value	Holding	Filing
Oct 22	Oct 21	David R. EpsteinDirector	Director	▲ BUY	10,000	8.88	$89K	+67%	Form 4 ↗
Oct 9	Oct 8	David R. EpsteinDirector	Director	▲ BUY	5,000	8.90	$45K	+50%	Form 4 ↗
Oct 7	Oct 6	Pierre Thadee Victor KemulaCFO	CFO	▲ BUY	10,000	8.59	$86K	New	Form 4 ↗
Oct 7	Oct 5	Tim Jasper KnotnerusCEO	CEO	▲ BUY	6,000	8.48	$51K	+55%	Form 4 ↗
Oct 7	Oct 6	David R. EpsteinDirector	Director	▲ BUY	5,000	8.70	$44K	+100%	Form 4 ↗
Oct 7	Oct 6	Tim Jasper KnotnerusCEO	CEO	▲ BUY	5,000	8.70	$44K	+30%	Form 4 ↗
Oct 7	Oct 5	David R. EpsteinDirector	Director	▲ BUY	5,000	8.57	$43K	New	Form 4 ↗

Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings

Insiders who traded in the past year

Insider	Role	Buys	Bought	Sold	Latest
David R. Epstein	Director	4	$220K	$0	Oct 22, 2026
Pierre Thadee Victor Kemula	CFO	1	$86K	$0	Oct 7, 2026
Tim Jasper Knotnerus	CEO	2	$94K	$0	Oct 7, 2026

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →